Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from PD-1/PD-L1 blockade, largely because of immunosuppression. New immunotherapy-based combinations are under investigation in an attempt to improve outcomes. <...
Main Authors: | Iosune Baraibar, Marta Roman, María Rodríguez-Remírez, Inés López, Anna Vilalta, Elisabeth Guruceaga, Margarita Ecay, María Collantes, Teresa Lozano, Diego Alignani, Ander Puyalto, Ana Oliver, Sergio Ortiz-Espinosa, Haritz Moreno, María Torregrosa, Christian Rolfo, Christian Caglevic, David García-Ros, María Villalba-Esparza, Carlos De Andrea, Silvestre Vicent, Rubén Pío, Juan José Lasarte, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3169 |
Similar Items
-
Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01) -
PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
by: Tiina Vesterinen, et al.
Published: (2019-08-01) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01) -
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
by: Fan Y, et al.
Published: (2016-10-01) -
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
by: Xianjie Jiang, et al.
Published: (2019-01-01)